Rubedo Senolytics: The Golden Startup of Longevity

Whenever anti-aging is discussed in the media, the conversation drifts to familiar topics: intermittent fasting, metformin, resveratrol, spermidine. But behind the scenes, far from consumer headlines, an entire industry is quietly being built: longevity biotech. Billions of dollars are flowing from venture capital funds into startups trying to crack aging in molecular terms and translate that cracking into drugs that will pass FDA regulatory review.

In a publication by Longevity.Technology from April 17, 2026, the spotlight was turned on one of the most interesting players in the field: Rubedo Life Sciences, a San Francisco-based startup specializing in developing AI-based senolytics. The company raised over $60 million in a Series B round, is leading an experimental drug called RLS-1496 in active clinical trials, and uses a platform it calls 'the senolytic alchemist,' an AI system that scans millions of molecular structures and predicts which ones will kill harmful zombie cells without harming healthy cells.

This article is not just about Rubedo. It is a glimpse into an entire industry. When you see a small startup raising $60 million just to kill aging cells, and when you discover that dozens of other companies of similar size are operating in parallel, you begin to understand that the aging field has passed a tipping point. It has left academia and entered the commercial world. The question is no longer 'whether aging can be treated,' but 'who will bring the first drug to market, and when.'

What is Rubedo Life Sciences?

The name Rubedo is derived from classical alchemy. In the mystical tradition of the Middle Ages, rubedo (red) was the final stage of the alchemical process, the transformation of base metal into gold, or of the soul into purity. The choice of name is no coincidence. The company sees itself as translating the principle of transformation: turning aging and harmful cells into healthy, functional tissue.

• Founded in 2020 by founder and CEO Dr. Marco Conte, an Italian-American scientist who worked for many years in cellular aging research at the Buck Institute.
• Based in San Francisco, with additional labs in Europe, and currently employs about 50 people, mostly cell biology scientists, medicinal chemists, and AI experts.
• The ALEMBIC platform, a computational system that combines machine learning with molecular biology models, capable of scanning tens of millions of molecules per day.
• A drug pipeline of 4-5 candidates, with the lead being RLS-1496 for pulmonary fibrosis (IPF), which has already entered human clinical trials.
• Total cumulative investment of about $100 million from three funding rounds, with top-tier investors: Khosla Ventures, AbbVie Ventures, and others.

The founder, Dr. Conte, left academia after seeing in the lab that the bottleneck for developing senolytic drugs was not the biology itself, but the ability to scan molecules quickly and accurately. Choosing which molecule among millions would kill a zombie cell without harming a healthy cell was then a task of years of manual work. AI changed the equation.

The Connection to AI: A Surprising Mechanism

What makes Rubedo different from the first generation of senolytics companies like Unity Biotechnology is the hybrid approach: combining deep biological expertise with advanced artificial intelligence. Instead of testing thousands of molecules manually in the lab, ALEMBIC allows predicting molecular properties in real time.

The method works in several stages. The first stage: mapping zombie cells at the single-protein level. The company used single-cell proteomics to precisely characterize the differences between harmful aging cells and healthy cells. They identified dozens of proteins that appear only on the surface of zombie cells, and internal signatures that distinguish cells that need to be eliminated.

The second stage is training neural networks on molecular databases. ALEMBIC reads the chemical structure of a molecule and predicts: will it bind to a target protein? Will it cause cell death? Will it be toxic to the kidneys or liver? This model is trained on public databases like ChEMBL and PubChem, along with unique data the company collected.

The third stage is laboratory confirmation of dozens of top molecules, known as hit confirmation. Only molecules that pass the computational filter reach actual biological testing. This saves the company years of work and millions of dollars.

This approach is similar to what other AI companies like Daphne Koller's Insitro or Recursion Pharmaceuticals do, but focused on aging. This is the transition of the biotech field to an era where software, not just chemistry, is the bottleneck of innovation.

Current Evidence

RLS-1496: Rubedo's Lead Drug

RLS-1496 is an experimental drug in the class of small molecule senolytics, a small molecule taken orally that targets the BCL-XL protein in zombie cells. The BCL-XL protein prevents cell death in aging cells, thus allowing them to stay alive without functioning. Inhibiting it causes zombie cells to die by apoptosis, while healthy cells, which are not as dependent on BCL-XL, remain unaffected.

The interesting thing is that this is a known class. Venetoclax, an approved drug for blood cancer, also blocks BCL-XL and BCL-2. But it is toxic to blood platelets, which limits its use as a general senolytic. RLS-1496 was specifically designed to be selective for the BCL-XL protein and spare platelets.

The current clinical trial is a Phase 1 in patients with idiopathic pulmonary fibrosis (IPF), a fatal inflammatory disease that leads to lung scarring and death within 3-5 years of diagnosis. IPF was chosen because studies have shown that zombie cells in the lungs are the main driver of the disease. The trial includes 30 participants in the first stage, aiming to determine safety and maximum dosage. Initial results are expected by the end of 2026.

The Series B Funding Round

The $60 million funding round in 2026 led to a significant change in the company. Before the round, Rubedo operated as a small research startup. After the round, the company expanded to 50 employees, opened a second lab in Europe, and purchased advanced cell imaging equipment costing millions of dollars. The lead investor in the round was AbbVie Ventures, the venture capital arm of pharmaceutical giant AbbVie. AbbVie's involvement is not just money; it also provides access to the regulatory and commercial network of the pharmaceutical giant.

What is particularly interesting is that investors are insisting on clinical milestones, not just research ones. The previous generation of anti-aging companies raised funds based on a 'vision' of longevity. The current generation, including Rubedo, must show safety data, efficacy, and results in real patients. This is the maturity of the field.

The ALEMBIC Platform: The Data

The company reported at the J.P. Morgan Healthcare conference in 2025 on the platform's performance. ALEMBIC scanned 47 million molecules and identified 3,200 potential candidates for senolytics. Of these, 280 passed laboratory confirmation, 22 moved to testing in mice, and 3 advanced to the preclinical phase. The numbers indicate a success rate significantly higher than the industry average, which typically requires millions of tests to get one candidate.

Academic Collaborations

Rubedo collaborates with Buck Institute, Mayo Clinic, and Stanford. These collaborations are not just for publicity; they also provide the company with access to patient samples, mechanism studies, and patent registries. The close connection to academia is what distinguishes the new generation of anti-aging biotech: not as a commercial black box, but as an industrial extension of academic research.

What About the Other Giants in the Field?

Rubedo is not the only startup in anti-aging, far from it. In 2026, the field consists of a variety of companies with very different approaches. Understanding the full landscape is essential to assess Rubedo's position.

• Altos Labs: The most funded startup in the world in the field, raised $3 billion in 2022 from investors including Jeff Bezos and Yuri Milner. Focuses on cellular reprogramming using Yamanaka factors. The approach: not to kill zombie cells, but to 'reboot' them to be younger. Still in early research stage, with no drugs in trials.
• Calico Labs: Alphabet's (Google) longevity arm, founded in 2013, funded with billions, but suffers from a reputation of 'more words than results.' Works on searching for basic mechanisms of aging.
• Retro Biosciences: A startup funded by Sam Altman (CEO of OpenAI), raised $180 million. Focuses on cellular reprogramming but also on senolytics. Stands out due to its connection to Altman and the AI world.
• BioAge Labs: A California startup working on a drug for sarcopenia and body composition changes. In Phase 2 clinical trials, one of the closest drugs to FDA approval.
• Unity Biotechnology: The first generation of senolytics, suffered a resounding failure in 2020 when its lead drug failed a trial for osteoarthritis. The company has optimized and is working on drugs for the eyes. Considered a warning for the field.
• Loyal: A startup developing a drug for dog longevity, which already received initial FDA approval in 2024. The logic: prove it on dogs before humans.
• Life Biosciences: Works on a combination of approaches, mainly a drug for age-related vision loss. In Phase 1.

What is particularly interesting is that Rubedo is in a sweet spot: not an inflated giant like Calico, nor an early bet like Altos, but a company that already has a drug in the clinic. This is where investors like to be, because the statistical chance of a positive outcome is highest.

Should We Start Investing in Rubedo or Buying RLS-1496?

This question requires a clear distinction. RLS-1496 is not available to the public. It is in a Phase 1 clinical trial, meaning it is only given to IPF patients participating in that specific trial. There is no way to buy it, no way to take it as a supplement, and no expectation of FDA approval in the coming years.

Even if the trial succeeds, the path to approval is long. Phase 1 tests safety. Phase 2 tests initial efficacy. Phase 3 tests large-scale efficacy. Only after all this comes FDA approval, and years later it reaches Israel. The reasonable expectation: RLS-1496 will not be available to Israeli citizens before 2030, and in all likelihood only after 2032.

Investment Risk

Rubedo is not a public company. You cannot buy its shares on the stock exchange. Investment is only available to institutional investors in its funding rounds. Even if the company goes public in the future, statistically, most biotech startups fail. 9 out of 10 experimental drugs do not reach FDA approval. Investing in individual companies in the anti-aging field is a high-risk bet.

What About the Expected Price?

Even if RLS-1496 succeeds and reaches the market, the price is expected to be high. Targeted senolytic drugs are expected to cost $10,000-$50,000 per annual treatment cycle. Insurance will cover this only for recognized diseases like IPF, not for general anti-aging treatment. The expectation that it will become accessible to the general public is not realistic in the coming decade.

Open Questions About the Mechanism

Despite the expectations, there are question marks about the scientific approach as well. A selective BCL-XL blocker, even if it spares platelets, could still damage other cells that depend on this protein, such as heart muscle cells. Clinical trials will test this rigorously, and there is no guarantee of long-term safety.

The Risk of 'Commercial Anti-Aging' is Unrelated

It is important not to confuse Rubedo, a serious biotech company with controlled clinical trials, with hundreds of wellness companies selling 'senolytic supplements' for thousands of dollars without clinical validation. Most of these supplements are ineffective, and some are even dangerous. The Israeli consumer looking for 'anti-aging' must distinguish between the gray market and serious research.

What Should We Take from This Research?

1. Understanding the industry is a first step. Follow professional journals like Longevity.Technology, STAT News, and Endpoints to understand which startups are advancing, which drugs are in the clinic, and which approaches are gaining traction.
2. Do not buy 'senolytic supplements' from wellness companies. If a company sells a product and offers longevity without controlled clinical trials, it is a red flag. A real drug goes through the FDA, not sold on Instagram sites.
3. If you have a specific disease being treated in a trial, consider participating. Patients with IPF, osteoarthritis, Alzheimer's, and others can find active trials on clinicaltrials.gov. Participation provides access to cutting-edge treatments for free.
4. Invest in yourself, not in a startup. Until anti-aging drugs reach the market, the interventions with the strongest scientific basis are basic: physical activity, quality sleep, Mediterranean diet, stress management, and social connections. These will give you 80% of the benefit at about 1% of the cost.
5. Be skeptical but not cynical. The longevity field is a mix of real science and marketing hype. An approved anti-aging drug will come, the question is only when. Healthy skepticism, but scientific openness, is the right approach.
6. Strengthen your immune system. A strong immune system removes zombie cells naturally. Vitamin D, sleep, physical activity, and intermittent fasting all activate endogenous senolytic processes. This is the senolytic available to everyone today.
7. Understand the difference between 'research' and 'drug'. An interesting biological discovery in the lab is not a drug. Between discovery and approved drug, 10-15 years and billions of dollars pass. Do not rush your expectations because of media headlines.

The Broader Perspective

The story of Rubedo Life Sciences is much more than about one company. It is a marker of the maturity of an entire field. A decade ago, senolytics was an academic idea studied at conferences. Today, it is a multi-billion dollar industry with AI platforms, regulatory collaborations, and documented clinical trials.

This is also an opportunity to see the field honestly. Longevity is not a 'supplement industry', it is a real drug industry, with all the difficulties and costs that entails. A serious senolytic drug goes through 10-15 years of development, requires an investment of a billion dollars, and has a 10% chance of reaching the market. This is not something that can be advanced by extreme diets or wellness companies.

Think about the history of cancer drugs. In the 1960s, cancer was a certain death sentence. Today, some types of cancer are curable at a rate of 90%. This change did not happen overnight; it happened thanks to tens of thousands of researchers, hundreds of companies, and tens of thousands of clinical trials. Longevity will go through a similar process, only we are still at its beginning.

Rubedo, and similar companies, are the 'first generation' of longevity biotech. They are creating an infrastructure of knowledge, platforms, and trials, on which the next generation and the one after it will be built. Even if RLS-1496 fails, the learning from it will benefit dozens of future drugs. Even if Rubedo closes, ALEMBIC may reach another company and accelerate further developments.

It is also important to understand the geopolitics of the longevity field. Most serious startups operate in the United States, with a spread in Europe. China is investing heavily in the field but focuses more on basic research. Israel, despite its general technological strength, has not yet managed to build a prominent longevity biotech startup on a global scale. This is a future opportunity for Israeli investors and entrepreneurs.

And finally, let's return to the human point. An anti-aging drug, even when it arrives, will not be a magic pill. It will be one tool in a toolbox. Lifestyle, genetics, environment, stress, and social connections will continue to be the decisive factors in personal longevity. The role of the biotech industry is to add another option, not to replace the basics.

Rubedo Life Sciences, in its alchemical name, reminds us of the great promise: turning our zombie cells into young tissue again, turning aging from hopelessness into a treatable target, turning science from promise into reality. The road is still long, but the labs are working, the trials are running, and the capital is flowing. The era of reversible aging is being built, brick by brick, by startups like Rubedo. And that, in itself, is a reason for cautious optimism.

References:
Longevity.Technology - Rubedo: The Senolytic Alchemist of Aging Biology
Rubedo Life Sciences - Official Website